Panelists discuss the future of chronic obstructive pulmonary disease (COPD) management, emphasizing the need for long-term data on newly approved therapies, the development of refined biomarkers like FeNO and imaging tools to guide precision treatment, and the potential for earlier intervention with biologics—all aimed at advancing personalized care and altering the disease trajectory in high-risk patients.
Panelists discuss the evolving role of newly approved chronic obstructive pulmonary disease (COPD) therapies—such as ensifentrine, mepolizumab, and dupilumab—in addressing persistent symptoms and frequent exacerbations despite standard care, highlighting their targeted use based on patient profiles, the practical challenges of integration into clinical practice, and the importance of education, shared decision-making, and personalized care to optimize outcomes in moderate to severe COPD.
Panelists discuss the impact of newly approved therapies for chronic obstructive pulmonary disease (COPD)—such as ensifentrine, mepolizumab, and dupilumab—highlighting their diverse mechanisms and potential to personalize treatment for patients with persistent symptoms or type 2 inflammation, while emphasizing the importance of guideline integration, clinician education, and collaboration across care teams to ensure timely and effective adoption in clinical practice.
The panel concludes the discussion with key takeaways on the evolving treatment landscape for COPD.
Experts on respiratory diseases discuss the role of primary care providers in the treatment of patients with COPD.
Clinical insights on the relationship between comorbidities in COPD and how multimorbidity plays a role in treatment decisions.
Focusing on evolving therapeutic paradigms for patients with COPD, experts discuss the importance of earlier diagnosis and treatment.
Experts share perspectives on the future treatment landscape for patients with COPD, highlighting the importance of precision medicine and the remaining unmet needs.
The panel discusses emerging treatment approaches in COPD and reviews the study design and topline results from the BOREAS trial investigating dupilumab.
Igor Barjaktarevic, MD, PhD, discusses the evolving treatment landscape in COPD, highlighting current treatment approaches and novel therapies on the horizon.
Experts on respiratory diseases discuss the GOLD treatment guidelines for COPD and discuss research that is informing treatment strategies.
Focusing on the role of eosinophils in diagnosing COPD, the panel discusses how often they should be tested, the cut-off value, and the natural changes of eosinophils in the disease course.
The panel discusses unmet needs in the COPD treatment landscape, highlights the shortcomings of current treatment strategies, and provides insights on diagnostic practices.
Igor Barjaktarevic, MD, PhD, provides insights on the evolving role of biomarkers in COPD, highlighting the role of eosinophils on informing treatment decisions.
1) Nicola A. Hanania, MD, MS, discusses what we have learned from asthma research on the involvement of type 2 inflammation that is applicable to COPD.
The expert panel offers insights on the concept of extending phenotypes into treatable traits in patients with COPD.
Three experts on respiratory diseases give an overview of chronic obstructive pulmonary disease (COPD) and its impact on patients and the healthcare system.
